Not Yet RecruitingPhase 1/2

Precision Microbiota Interventions for Senoreduction Trial

United States160 participantsStarted 2026-04-01

Plain-language summary

People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥40 years * People with HIV * Recent alcohol use defined as ≥42 grams in the prior week and positive urine ethyl glucuronide (EtG) Exclusion Criteria: * Probiotic use in past 3 months * Recent antibiotics or immunosuppressives * Allergy to study products * Pregnancy or breastfeeding * Inability to comply

What they're measuring

Change in circulating senescent T cell numbers

Timeframe: Time 0 to Week 4 of treatment period

Trial details

NCT IDNCT07462767

SponsorLouisiana State University Health Sciences Center in New Orleans

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-12-01

Contact for this trial

David A Welsh, MD

United States dwelsh@lsuhsc.edu

View on ClinicalTrials.gov More HIV Infections trials